(ABBV) - Analyzing AbbVie's Short Interest
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie (ABBV.US) seeks expedited approval in the usa for Teliso-V for the treatment of non-small cell lung cancer.
Biopharmaceutical company AbbVie (ABBV.USA) announced on Friday that it has applied to the United States Food and Drug Administration for accelerated approval of its antibody-drug conjugate for a certain type of lung cancer patients. The company stated that the application covers telisotuzumab vedotin or teliso-V, for the treatment of adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor wild-type, non-squamous non-small cell lung cancer with c-Met protein overexpression.
AbbVie's Parkinson's Drug Tavapadon: A Market Perform Rating Amidst Competitive Landscape and Clinical Trials
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer